Looking for help with what large outpatient infusion centers do in regards to monitoring patients with Taxol, Rituxan and Daratumumab, (and other antibodies)
We are looking to standardize across our academic center and health systems, but also find there is a wide range of discrepancy as to monitoring. Is it vital signs? Can monitoring look like nurses using critical thinking and assessment to either include vital signs or other assessments?
Sherry Looker, RN, BSN, OCN I Ambulatory Nurse Manager I Gonda 10 E Cancer Treatment Unit I Dept of Medical Oncology I Mayo Clinic I 200 First Street SW I Rochester, Mn 55905 I email@example.com I Office 507- 284-5283 I Pager 3-6438
I developed a Quick Reference Sheet for out and inpt nurses that lists the various medications ,the premeds /if needed and frequency of monitoring. It started out with just Rituxan and Taxol and as you can imagine it has grown tremendously from 1 side of 1 page to now 4.5 pages...I would be happy to share it with you and others...
That would be very helpful. Thank you
I would like a copy also, please.
Barbara Hartman, RN, OCN, BSN
Nurse Manager, Cancer Institute
Rush Riverside Cancer Institute
200 Riverside Drive
Bourbonnais, IL 60914
p 815-933-9660 ext 4092
http://www.RiversideMC.net | http://www.facebook.com/RiversideMC